Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J hit with $247 million verdict in hip implant trial

A federal jury in Dallas ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Read More »

All Systems Go: Johnson & Johnson Reaches Out for Second Ionis GI Drug

Ionis Pharmaceuticals and Janssen strengthened their alliance with a second deal for gastrointestinal drugs. Janssen put up $5 million to secure the licensing of Ionis’ antisense drug, IONIS-JBI2-2.5RX.

Read More »

FDA announces comprehensive regenerative medicine policy framework

The U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

Read More »

Sangamo Scores Bragging Rights for First-in-Human Gene Editing Trial

Barely a week after announcing it was moving into a new corporate headquarters, Sangamo Therapeutics announced that the company has dosed the first patient in its Phase I/II gene therapy trial.

Read More »

Sandoz says new clinical data support two biosimilars

Novartis’ generics division Sandoz said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab.

Read More »

U.S. approves digital pill that tracks when patients take it

U.S. regulators approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.

Read More »

Argos Reports Positive Kidney Cancer Data

Argos Therapeutics announced positive interim data for the company’s kidney cancer drug Rocapuldencel-T from a Phase III clinical trial.

Read More »

Prescription-strength steroid creams sold without prescription

Although the U.S. requires prescriptions for topical steroids with more than a 0.5% concentration, much stronger and potentially harmful steroid creams are not hard to find without a prescription, doctors report.

Read More »

Sage soars as postpartum depression drug moves closer to approval

Sage Therapeutics Inc.’s postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

Read More »

Boehringer, MiNA Therapeutics Forge NASH Deal

Boehringer Ingelheim struck a deal targeting liver disease with MiNA Therapeutics.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom